Epstein-Barr Virus Antibody to Early D Antigen (EA-D), IgG
Also known as: EBV EAD
Use
May aid in the diagnosis of acute Epstein-Barr virus (EBV) infection and EBV reactivation in conjunction with other serologic studies. Molecular tests are preferred to detect EBV reactivation. It is not a standalone test and should be used as part of a panel of tests to support diagnosis in clinical settings.
Special Instructions
EBV EA-D values obtained with different manufacturers' assay methods may not be used interchangeably. Parallel testing is preferred, and convalescent specimens must be received within 30 days from receipt of the acute specimens. Label specimens plainly as 'acute' or 'convalescent.'
Limitations
The magnitude of the reported EBV EA-D level cannot be correlated to an endpoint titer. This test is not a standalone diagnostic tool and should not be used as the sole basis for diagnosis. It should be interpreted in conjunction with other laboratory findings and clinical information.
New York Approved
Methodology
Immunoassay (CLIA)
Biomarkers
LOINC Codes
- 50969-5
Result Turnaround Time
1-2 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
2 mL
Minimum Volume
0.5 mL
Container
ARUP standard transport tube
Collection Instructions
Allow specimen to clot completely at room temperature. Separate serum from cells ASAP or within 2 hours of collection.
Causes for Rejection
Contaminated, heat-inactivated, icteric, or grossly hemolyzed specimens.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 48 hours |
| Refrigerated | 2 weeks |
| Frozen | 1 year |
Other tests from different labs that may be relevant